Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) was first observed in extracts of colonic carcinoma tissue. Elevated levels are found in serum from patients with a wide variety of tumor types including gastrointestinal, lung, breast, ovary, and uterus. The frequency of elevated CEA levels increases with the Duke's stage of colonic carcinomas. High levels are more likely in the presence of metastatic disease and prognostically indicate a greater likelihood of metastasis. Levels will usually fall following successful treatment and remain stable. Rising levels in these patients may indicate recurrence. CEA is often elevated in liver disease and slightly elevated in smokers.

Swiss-Prot Accession Number: P06731


 
Therapy Indications
 
Myriad RBM Publications Publications
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine (2018) Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG Translational Oncology
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) Deming Y, Xia J, Cai Y, Lord J, Del-Aguila JL, Fernandez MV, Carrell D, Black K, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Bailey M, Ridge PG, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Holtzman D, Morris JC, Bales K, Pickering EH, Lee J, Heitsch L, Kauwe J, Goate A, Piccio L, Cruchaga C Scientific Reports
High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia (2016) Wehler CA, Preskorn, SH Journal of Clinical Psychiatry
Effects of Acute Endurance Exercise on Plasma Protein Profiles of Endurance-Trained and Untrained Individuals over Time (2016) Schild M, Eichner G, Beiter T, Zuegel M, Niess AM, Steinacker JM, Mooren FC Mediators of Inflammation
Sjögren’s Syndrome Patients with Ectopic Germinal Centers Present with a Distinct Salivary Proteome (2016) Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R Rheumatology
Towards a Blood-Based Diagnostic Panel for Bipolar Disorder (2016) Haenisch F, Cooper JD, Reif A, Kittel-Schneider S, Steiner J, Leweke FM, Rothermundt M, Van Beveren NJM, Crespo-Facorro B, Niebuhr DW, Cowan DN, Weber NS, Yolken RH, Penninx BWJH, Bahn S Brain, Behavior, and Immunity
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (2015) Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H and Talpaz M Blood Cancer Journal
Serum Proteomic Profiling of Major Depressive Disorder (2015) Bot M, Chan MK, Jansen R, Lamers F, Vogelzangs N, Steiner J, Leweke FM, Rothermundt M, Cooper J, Bahn S, Penninx BWJH Translational Psychiatry
Development of a Blood-Based Molecular Biomarker Test for Identification of Schizophrenia before Disease Onset (2015) Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H, Rothermundt M, Steiner J, Leweke FM, Van Beveren NJM, Niebuhr DW, Weber NS, Cowan DN, Suarez-Pinilla P, Crespo-Facorro B, Mam-Lam-Fook C, Bourgin J, Wenstrup RJ, Kaldate RR, Cooper JD, Bahn S Translational Psychiatry
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease (2012) Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; for the Alzheimer's Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group Arch Neurol. 2012 Jul 16:1-8
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab (2012) Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A Ann Rheum Dis. 2012 Sep 12. [Epub ahead of print]
Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD (2010) Devanarayan V, Scholand MB, Hoidal J, Leppert MF, Crackower MA, O'Neill GP, Gervais FG COPD 7: 51-58.
Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia (2010) Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, (JM) van Beveren N, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S Biomark Insights5: 39–47.
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study (2010) Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C Arthritis Res Ther. 12:R211